Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research. Materials and Methods We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues. Results Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023). Conclusion PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.
Abstract
Purpose Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research. Materials and Methods We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues. Results Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023). Conclusion PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.
참고문헌 (22)
- Duffy MJ, "The war on cancer: are we winning?", Tumour Biol, 34, pp.1275~1284 (2013)
- Scott CL, "Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment", Front Oncol, 3, pp.295~ (2013)
- Stordal B, "BRCA1", 2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation, 2013, pp.7, 567~579
- Tentler JJ, "Patient-derived tumour xenografts as models for oncology drug development", Nat Rev Clin Oncol, 9, pp.338~350 (2012)
- Boone JD, "Ovarian and cervical cancer patient derived xenografts : the past, present, and future", Gynecol Oncol, 138, pp.486~491 (2015)
- Lee CH, "Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice : potential models", Gynecol Oncol, 96, pp.48~55 (2005)
- Press JZ, "Xenografts of primary human gynecological tumors grown under the renal capsule of NOD", SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy, 2008, pp.110, 256~264
- Watanabe H, "New response evaluation criteria in solid tumoursrevised RECIST guideline (version 1.1)", Gan To Kagaku Ryoho, 36, pp.2495~2501 (2009)
- Oh DY, "HER2 as a novel therapeutic target for cervical cancer", Oncotarget, 6, pp.36219~36230 (2015)
- Staflin K, "Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease(SCID)mouse model of human ovarian carcinoma", Int J Gynecol Cancer, 16, pp.1557~1564 (2006)
- Sangodkar J, "Targeting the FOXO1", KLF6 axis regulates EGFR signaling and treatment response, 2012, pp.122, 2637~2651
- Sereni MI, "Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping : implications for personalized cancer therapy", Proteomics, 15, pp.365~373 (2015)
- Dobbin ZC, "Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer", Oncotarget, 5, pp.8750~8764 (2014)
- Elkas JC, "A human ovarian carcinoma murine xenograft model useful for preclinical trials", Gynecol Oncol, 87, pp.200~206 (2002)
- Ricci F, "Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations", Cancer Res, 74, pp.6980~6990 (2014)
- Topp MD, "Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts", Mol Oncol, 8, pp.656~668 (2014)
- Weroha SJ, "Tumorgrafts as in vivo surrogates for women with ovarian cancer", Clin Cancer Res, 20, pp.1288~1297 (2014)
- Hidalgo M, "Patient-derived xenograft models : an emerging platform for translational cancer research", Cancer Discov, 4, pp.998~1013 (2014)
- Zhu G, "Comparison of two kinds of orthotopic xenograft models for human ovarian cancer", Eur J Gynaecol Oncol, 35, pp.724~727 (2014)
- Jin K, "Patient-derived human tumour tissue xenografts in immunodeficient mice : a systematic review", Clin Transl Oncol, 12, pp.473~480 (2010)
- Reyal, F, "Molecular profiling of patient-derived breast cancer xenografts", Breast Cancer Res, 14, pp.11~ (2012)
- Vergote IB, "Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma : a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study", J Clin Oncol, 32, pp.320~326 (2014)